Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Deffered Revenue (2016 - 2018)

Historic Non-Current Deffered Revenue for ImmunityBio (IBRX) over the last 5 years, with Q4 2018 value amounting to $2.7 million.

  • ImmunityBio's Non-Current Deffered Revenue fell 1762.41% to $2.7 million in Q4 2018 from the same period last year, while for Dec 2018 it was $2.7 million, marking a year-over-year decrease of 1762.41%. This contributed to the annual value of $2.7 million for FY2018, which is 1762.41% down from last year.
  • Latest data reveals that ImmunityBio reported Non-Current Deffered Revenue of $2.7 million as of Q4 2018, which was down 1762.41% from $2.9 million recorded in Q3 2018.
  • In the past 5 years, ImmunityBio's Non-Current Deffered Revenue registered a high of $3.6 million during Q2 2017, and its lowest value of $3000.0 during Q2 2015.
  • For the 5-year period, ImmunityBio's Non-Current Deffered Revenue averaged around $2.2 million, with its median value being $2.5 million (2016).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 6403333.33% in 2016, then crashed by 1762.41% in 2018.
  • Quarter analysis of 5 years shows ImmunityBio's Non-Current Deffered Revenue stood at $521000.0 in 2014, then soared by 62.19% to $845000.0 in 2015, then skyrocketed by 187.1% to $2.4 million in 2016, then skyrocketed by 37.06% to $3.3 million in 2017, then fell by 17.62% to $2.7 million in 2018.
  • Its Non-Current Deffered Revenue was $2.7 million in Q4 2018, compared to $2.9 million in Q3 2018 and $3.0 million in Q2 2018.